Drug Target Review

DECEMBER 20, 2024

Artificial intelligence (AI) has revolutionised many industries, yet its adoption in pharmaceutical drug development has been notably slower. For years, AI and machine learning (ML) were often dismissed as little more than advanced statistics with little practical value in drug development.

Clinical Trials 128

Clinical Trials Trials Pharmaceuticals Drug Development 128

Alta Sciences

FEBRUARY 19, 2025

Regulatory Guidance for Oligonucleotide Bioanalysis in Drug Development pmjackson Wed, 02/19/2025 - 21:30 The unique physicochemical properties of oligonucleotides require the use of specialized bioanalytical approaches, with key considerations including selectivity and specificity, sensitivity, stability, and matrix effects.

Drug Development 52

Drug Development Clinical Pharmacology Immune Response Drugs 52

PPD

MARCH 11, 2025

Developing treatments for individuals living with rare diseases is critical, but orphan drug development is laden with unique obstacles that necessitate innovative, multifaceted approaches. RWE is transforming rare disease drug development, providing the insights needed to overcome unique challenges.

Drug Development 52

Drug Development Clinical Trials Disease Trials 52

Drug Patent Watch

DECEMBER 11, 2024

In this article, we will delve into the key criteria for selecting a CDMO, highlighting the essential factors to consider and the importance of effective communication and cultural fit. Your Drugs Development Stage The stage of your drug development is a critical factor in selecting a CDMO.

Pharmaceutical Companies 95

Pharmaceutical Companies Compliance Pharmaceuticals Drug Development 95

Drug Patent Watch

FEBRUARY 12, 2025

Accelerating Generic Drug Development: Strategies for Success As a pharmaceutical professional, you know how crucial it is to navigate the complex landscape of generic drug development. The generic drug development process involves several stages, from patent research to regulatory approvals.

Drug Development 62

Drug Development Drugs Compliance Regulations 62

Chemical Biology and Drug Design

MAY 10, 2025

The review focused on English-language original research and review articles, examining carprofen and its derivatives in terms of their synthesis methods as well as their use as small molecules in various therapeutic applications, both human and veterinary.

Small Molecule 100

Small Molecule Drug Development Science Therapies 100

Crown Bioscience

JULY 1, 2025

These “ biological missiles ” represent an exciting new advance in anti-cancer therapies and are one of the fastest-growing segments in oncology drug development.

Drugs 52

Drugs Drug Development Therapies Research 52

Crown Bioscience

JULY 21, 2025

In the complex landscape of oncology research and drug development, reliable preclinical models are crucial. Among various available platforms, cell line-derived xenografts (CDX) stand out as a robust and highly valuable model system, offering unique advantages for understanding tumor biology, drug efficacy, and therapeutic potential.

Drugs 52

Drugs Drug Development Research 52

Crown Bioscience

JUNE 23, 2025

Drug resistance remains one of the most pressing challenges in oncology drug development, as it is the leading cause of treatment failure. As researchers look to understand and overcome drug resistance, they need precise, controllable, and scalable models that allow them to isolate and study resistance mechanisms effectively.

Drugs 52

Drugs Drug Development Therapies Treatment 52

Drug Target Review

MARCH 24, 2025

Sujeegar Jeevanandam, an expert with 13 years of experience in life sciences R&D, offers valuable insights into the current state and future trajectory of artificial intelligence in drug discovery. This breakthrough could fundamentally change how drugs are developed and tested.

Clinical Trials 59

Clinical Trials Animal Testing Drugs Pharmacokinetics 59

Drug Patent Watch

MARCH 3, 2025

Breaking Down Barriers: The Power of Global Research Collaborations in Generic Drug Development As the world grapples with the complexities of healthcare, one thing is clear: the need for innovative solutions has never been more pressing. The benefits of international collaborations in generic drug development are multifaceted.

International 70

International Drug Development Drugs Treatment 70

Drug Target Review

DECEMBER 6, 2024

In drug discovery and biological research, the scientists workflow often follows a structured and iterative approach to ensure accuracy, reproducibility and scientific integrity. At the heart of any research is the scientific question.

RNA 52

RNA Drugs Research Science 52

Drug Target Review

APRIL 7, 2025

In a recent survey conducted by ICON, Plc, biomarker selection was identified by 35 percent of respondents as a top challenge among drug developers for phase I trials, second only to navigating regulatory compliance (- 38 percent). Silver Spring (MD): Food and Drug Administration (US); 2016-. 113:9861002.

Clinical Development 69

Clinical Development Clinical Trials Clinical Pharmacology Trials 69

Drug Target Review

DECEMBER 11, 2024

This issue poses a significant hurdle for drug developers, with no universal protocol currently in place to address these complexities. In this article, we share our hard-earned insights into overcoming these critical challenges.

International 52

International Laboratories Drugs Pharmacokinetics 52

Drug Target Review

JANUARY 14, 2025

In the next article, we will discuss the tools scientists can use to execute the workflow described in Figure 1. Figure 1: High-level workflow for early drug discovery. In 2003, he was selected by EE Times as one of the top 13 most influential people in the semiconductor industry.

Drugs 69

Drugs Protein Expression Science Research 69

Drug Target Review

JUNE 11, 2025

Drug development is plagued by complex challenges, but multimodal AI is unlocking new opportunities. By integrating diverse data sources – from genomics to clinical insights – this approach is accelerating drug discovery, improving patient stratification and boosting success rates. Highlighting data integration.

Drugs 65

Drugs Clinical Trials Drug Development Pharmaceuticals 65

Drug Target Review

JUNE 16, 2025

By complementing traditional analytical methods, it provides a more accurate representation of drug behaviour to support translational and pre-clinical studies. This article explores the principles, applications and future potential of MSI in drug development. 2024, Article ASAP. Proteome Res.

Drugs 52

Drugs Organic Chemistry Laboratories Pharmaceuticals 52

FDA Law Blog: Drug Discovery

APRIL 21, 2025

One area drawing increasing attention is how these changes will affect the drug development and review process. As reported by the Wall Street Journal last week , reviews of both innovative and follow-on drugs have been caught in a traffic jam, largely due to a leadership vacuum at the Center for Drug Evaluation and Research (CDER).

FDA 64

FDA Drug Development Drugs International 64

Drug Target Review

JUNE 6, 2025

Image credit: Crystal Eye Media / Shutterstock The role of SPICA and manufacturing capabilities Drug development in the radiopharmaceutical space is particularly resource intensive. He stresses the importance of recognising organisational strengths and weaknesses: “No single company is fully expert in all aspects of drug development.”

Therapies 100

Therapies Treatment Drug Development Clinical Development 100

Drug Target Review

JUNE 9, 2025

A personal journey to Alltrna Michelle Werner’s career has spanned over 20 years in the pharmaceutical industry, where she developed her expertise in oncology drug development at leading companies such as Bristol Myers Squibb, AstraZeneca, and Novartis.

Disease 80

Disease Treatment Engineering Protein Production 80

Drug Target Review

JULY 8, 2025

As Vice President of Oncology Early Development (OED) at AbbVie , she leads the charge on translating bold scientific ideas into real-world impact – and she’s doing it with a focus on some of the most tenacious cancers out there. Her team sits right at the edge of innovation, where discovery science meets clinical execution.

Therapies 52

Therapies Science Drug Development Treatment 52

Drug Target Review

JUNE 17, 2025

Integrated multiomics is the future The impact on drug development could be profound. Such insights are invaluable in oncology, immunology and neuroscience, where structure-function relationships are critical. Integrated multiomics can accelerate target discovery by revealing causative pathways that span molecular layers.

RNA 72

RNA Engineering DNA Disease 72

Drug Target Review

DECEMBER 23, 2024

This type of analysis is crucial for drug developers, providing a framework to identify and mitigate toxicity risks early in the design process. Furthermore, data from Phase I trials can serve as benchmarks for comparing exposure-AE relationships in new ADCs using the same linker-payload combinations.

Research 52

Research Treatment Therapies Drug Development 52

Drug Target Review

JULY 19, 2025

Tackling manufacturing bottlenecks through collaboration In the highly complex and evolving space of early-stage drug development, the path from research to scalable manufacturing is littered with challenges.

Therapies 52

Therapies Clinical Trials Trials Research 52

The Premier Consulting Blog

APRIL 13, 2025

On April 10, 2025, the US FDA announced that it has a long-term plan to eliminate conventional animal testing in drug development, starting with monoclonal antibodies (mAbs).[ from approved products in other countries) to inform doses and development. Legislation with delayed implementation In 2021, the FDA Modernization Act 2.0

Animal Testing 52

Animal Testing FDA Drug Development Production 52

Chemical Biology and Drug Design

JANUARY 21, 2025

ABSTRACT Infectious diseases, including bacterial, fungal, and viral, have once again gained urgency in the drug development pipeline after the recent COVID-19 pandemic. Compound 26 was identified as a promising antiproliferative hit. Tuberculosis (TB) is an old infectious disease for which eradication has not yet been successful.

Drug Development 100

Drug Development Disease Drugs Research 100

Drug Target Review

JULY 10, 2025

These core ADMET properties are fundamental to drug development across the industry, making them well-suited for pre-competitive collaboration. Instead, they focus on shared challenges – such as how different molecular structures are absorbed, metabolised or solubilised. Image credit: UGREEN 3S / Shutterstock.

Metabolic Stability 73

Metabolic Stability Drugs Drug Development Small Molecule 73

Drug Target Review

APRIL 30, 2025

The future of AI in CGT AI holds tremendous potential to reshape drug discovery and development in CGT. From precise target identification to optimised gene-editing techniques and streamlined clinical trial designs, AI has the capacity to transform every stage of the drug development pipeline.

Drugs 90

Drugs Therapies Clinical Trials Trials 90

Drug Target Review

DECEMBER 16, 2024

Dr Pooja Hingorani, Senior Medical Director of Oncology Early Development at AbbVie , shares her journey in STEM, from her early days in New Delhi to her impactful career in oncology research and drug development. Opportunities in clinical research and drug development were not always easy to come by.

Medical Schools 52

Medical Schools Clinical Research Drug Development Trials 52

Alta Sciences

MARCH 4, 2025

Over time, this group of professionals evolved and grew, having regular stakeholder interactions with the FDA and Controlled Substances staff to discuss requirements for drug developers. I have spent the better part of my career working to make drugs safer. About the Author Beatrice Setnik, PhD, Chief Scientific Officer.

Clinical Trials 52

Clinical Trials FDA Drug Development Trials 52

Perficient: Drug Development

MAY 27, 2025

Using the Blog plugin, individuals can publish articles, share insights, and engage with readers. Ideal for websites that need a news section, articles, or traditional blog features. Can include forms, analytics, and customer portals as needed. The backend is simple enough for non-technical users to create and manage posts.

Engineering 52

Engineering Testimonials Production Marketing 52

Drug Target Review

DECEMBER 9, 2024

Baker’s model could revolutionise drug development, synthetic biology, and nanotechnology, opening possibilities for new medical treatments, vaccines, nanomaterials, and sensors. Presumably, some of these compositions include proteins synthesised using Bakers AI model.

Engineering 106

Engineering International Drug Development Science 106

PPD

JULY 18, 2025

When a company applies these approaches, even small or novice drug developers will see increased efficiency. Meetings with the regulatory body, both virtually and in person, are key opportunities for alignment, strategy development, understanding expectations and risk reduction.

Regulations 52

Regulations Drug Development Clinical Trials Research 52

Drug Target Review

JUNE 28, 2025

DARPins – designed ankyrin repeat proteins – are small, engineered protein scaffolds with high specificity and affinity, developed as an alternative to traditional antibodies.

Science 52

Science Engineering Treatment Clinical Development 52

Alta Sciences

NOVEMBER 15, 2024

4 Essential Topics to Cover in Your First CRO Meeting pmjackson Fri, 11/15/2024 - 19:22 Starting a partnership with a contract research organization (CRO) is a sometimes intimidating—yet exciting—first step in your drug development journey. Lisa also suggests talking about your studies early on.

Drug Development 52

Drug Development Clinical Trials Trials Drugs 52

Drug Target Review

JULY 7, 2025

Non-human primates (NHPs), such as macaques and cynomolgus monkeys, have long served as a cornerstone in preclinical drug development due to their close genetic, anatomical and physiological resemblance to humans. Food and Drug Administration (FDA). Bailey J, et al. Trends in Non-Human Primate Use for Research and Testing.

Drug Research 52

Drug Research Research Animal Testing Drugs 52

Drug Target Review

JULY 11, 2025

Our mission as a company is to build the most impactful technologies that allow researchers and drug developers to understand underlying biology and ultimately use that to impact human health,” he says. Michael Schnall-Levin, Chief Technology Officer and founding scientist at 10x Genomics, has seen this transformation up close.

Molecular Biology 69

Molecular Biology Disease Therapies Bioinformatics 69